Selskabets formål er drift af og investering i forskning, udvikling, produktion og handel med biologiske løsninger, herunder bioteknologiske produkter og processer samt at drive virksomhed, der efter bestyrelsens nærmere bestemmelse står i forbindelse hermed. Selskabet tilstræber at drive sin virksomhed på bæredygtig og ansvarlig vis, herunder i økonomisk, miljømæssig og social henseende.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 116.7 mio. | 403.9 mio. | 944.3 mio. | 733.2 mio. | - | |
CVR: 30919246
Secondary names: NOVOZYMES BIOLOGICALS HOLDING A/S, Novozymes BioAg A/S
Compared to 220 companies in Leasing af intellektuelle ejendomsrettigheder og lignende produkter, dog ikke ophavsretsbeskyttede værker
Comparison is based on industry median values
Companies in the same industry and area
CVR 45944611
CVR 42794295
CVR 35207147
CVR 27985653
CVR 45644855
The financial health of Novonesis Plant Biosolutions A/S appears robust, with a significant profit of 403,926,577 DKK in 2024, up from 309,011,928 DKK in 2023. Revenue has shown a stable trend, increasing from 112,486,821 DKK in 2023 to 116,711,457 DKK in 2024, although it has declined from a peak of 148,562,040,000 DKK in 2022. The company's equity position remains strong at 733,197,785 DKK, indicating a solid foundation despite fluctuations in revenue. While the profit margins have improved notably, the substantial drop in revenue from 2022 raises concerns about long-term sustainability within the intellectual property leasing industry. Overall, Novonesis is well-positioned, but it must address revenue volatility to maintain its competitive edge.
AI-generated summary
companydata.dk